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Available online 9 April 2019Background: Left atrial appendage closure is a non-pharmacological alternative for stroke prevention in high-risk
non-valvular atrial fibrillation patients, but has not beenwidely studied in Asian patients. The prospectiveWASP
registry assessed real-world outcomes for patients undergoing WATCHMAN implant in the Asia-Pacific region.
Methods: Data were collected from consecutive patients across 9 centres. Major endpoints included procedural
success, safety and long-term outcomes including occurrence of bleeding, stroke/transient ischaemic attack/
systemic embolism and all-cause mortality.
Results: Subjects (n = 201) had a mean age of 70.8 ± 9.4 years, high stroke risk (CHA2DS2-VASc: 3.9 ± 1.7),
elevated bleeding risk (HAS-BLED: 2.1 ± 1.2) with 53% patients from Asian countries. Successful implantation
occurred in 98.5% of patients; 7-day device/procedure-related SAE rate was 3.0%. After 2 years of follow-up,
the rates of ischaemic stroke/TIA/SE and major bleeding were 1.9 and 2.2 per 100-PY, respectively, representing
relative reductions of 77% and 49% versus expected rates per risk scores. The relative risk reductions versus
expected rates were more pronounced in Asians vs. Non-Asians (89% vs 62%; 77% vs 14%). Other significant
findings included larger mean LAA ostium diameter for Asians vs. Non-Asians (23.4 ± 4.1 mm vs. 21.2
± 3.2 mm, p b 0.001) and hence requirement for larger median device size (27 mm for Asians, 24 mm for
non-Asians [p b 0.0001]).
Conclusion: Real-world experience of left atrial appendage closurewithWATCHMANhas demonstrated lowperi-
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Epidemiological studies have demonstrated significant differences
in ischaemic stroke risk and risk of bleeding in Asian populations with
non-valvular atrial fibrillation (NVAF) as compared with other ethnici-
ties [1–3]. Increased stroke risk commencing from a younger age, as
well as remarkably higher rates of intracranial bleeding, are some of
the considerations when tailoring stroke prevention treatment for pa-
tients of Asian ethnicity [1–4]. Left atrial appendage (LAA) closure
with the WATCHMAN device (Boston Scientific, Marlboro, MA, USA)
has emerged as a non-pharmacologic alternative that provides compa-
rable stroke protection while significantly lowering bleeding ratesthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
aide from ClinicalKey.com.au by Elsevier on October 29, 2020.
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device have not been broadly assessed in an Asian population; thus, our
prospective, multicentre registry aimed to collect real-world outcomes
for patients in the Asia-Pacific region.
2. Methods
2.1. Study population
The Registry on WATCHMAN Outcomes in Real-Life Utilization
(WASP) prospectively collected data on consecutive patients in the
Asia-Pacific region undergoing implantation of a WATCHMAN device
(NCT01972295). Certified implanting centres across Asia, Australia
and the Middle East were approached to participate. The registry used
identical design and study protocol to EWOLUTION [6]. Subjects were
recruited at clinical sites by physician discretion with appropriate local
and international guidelines to determine device eligibility. A contract
research organization provided independent monitoring of the data,
The study was approved by the respective institutional review boards
for human research, complies with the Declaration of Helsinki, and in-
formed consent was obtained from all participants.
2.2. Procedure
Procedures were performed by trained implanters and according to
the device's Directions for Use. Peri-procedural oral anticoagulation
(OAC) and intravenous (IV) heparin were managed at the Physician's
discretion. Implant of the LAA closure devicewas performed underfluo-
roscopic and transoesophageal echocardiographic (TOE) guidance as
previously described [5]. Post-procedural OAC was at the physician's
discretion and was individualised according to patient history and phy-
sician preferences.
2.3. Follow-up
Follow-up for subjects was based on local standard practice; gener-
ally a clinical visit at 1 to 3months post-procedure and annual follow-up
visits. Additional telephone contact was also undertaken. TOE imaging
was recommended at 6 weeks to reassess device position and any re-
sidual flow around the device. If satisfactory, OAC discontinuation and
initiation of dual-antiplatelet therapy (aspirin 81–325 mg, clopidogrel
75 mg) was recommended for 6 months post-implant or at physician
discretion. LAA occlusion was defined as satisfactory positioning of
the device at the ostium covering all trabeculated portions of the LAA
with no or minimal peri-device flow (b5 mm). Complete occlusion
was defined as no peri-device flow.
2.4. Serious adverse event reporting (SAE)
The trial required SAE reporting per ISO 14155 and theMEDDEV 2.7/
3 12/2010. Oversight was provided by sponsor medical safety review of
the source documents for all patient deaths. Events included procedure-
related complications (e.g., serious pericardial effusion, device emboli-
zation, procedure-related stroke), all deaths and events related to ex-
cessive bleeding (e.g., intracranial or gastrointestinal bleeding) scored
according to the BARC criteria [7]. Safety events were further classified
as procedure-, device- or OAC-related efficacy endpoints included any
occurrence of stroke (including ischaemic or haemorrhagic), transient
ischaemic attack (TIA), death, or systemic embolism (SE).
2.5. Primary endpoints
The primary endpoints of the study were procedural success and
safety, bleeding, all-causemortality and efficacy of the device to prevent
stroke/TIA/SE. Procedural success was defined as deployment and re-
lease of the device into the LAA with peri-device leak b 5 mm. ImpactDownloaded for Anonymous User (n/a) at The University of Adel
For personal use only. No other uses without permissioon bleeding was evaluated by comparing the observed bleeding
event rates with the expected rate predicted by HAS-BLED score [8].
Efficacy was tested by comparing the actual stroke event rate with the
CHA2DS2-VASc score predicted event rate [9].
2.6. Statistical methods
Country of implant was used as a surrogate for ethnicity with Asian
subjects defined as patients from Indonesia, Malaysia, Hong Kong,
Republic of Korea and Thailand; non-Asian subjects were defined as pa-
tients from Australia and Kingdom of Saudi Arabia. Australian subjects
were manually audited to identify any Asian patients. Continuous vari-
ables are summarized using the mean, standard deviation, range and
categorical variables with counts and percentages. Predicted risk of
annual stroke (in the absence of therapy) and bleeding (during antico-
agulant therapy) was extrapolated for each individual subject based
on CHA2DS2-VASc and HAS-BLED scores using published literature
[8,9] and then the average risk for the study population was used to de-
termine the expected rates for comparison to observed rates and risk re-
duction calculations. Rates of stroke, TIA, SE, death and bleeding events
are calculated as number of events per 100 patient-years (100-PY) and
estimates of rates and 95% confidence intervals (CI) for each subgroup
are derived from a Poisson Model. The Kaplan-Meier method was
used to describe SAE rates at specific time points in follow-up. Fisher's




Enrolment in WASP commenced in January 2014 and concluded in
October 2015, resulting in 201 patients across 7 countries including
Australia, Asia and theMiddle East. Australian and Saudi Arabian centres
enrolled 95 patients, while more than half of patients (106/201) were
from Asian countries (Indonesia, Malaysia, Hong Kong, Republic of
Korea, Thailand) (Fig. 1 e-supplement).
The mean age at consent was 70.8 ± 9 years (range 30–98) with
15.4% of patients aged ≥80 years and 67.2% male. Stroke risk scores
for CHADS2 and CHA2DS2-VASc were 2.5 ± 1.4 and 3.9 ± 1.7, respec-
tively, while the HAS-BLED score was 2.1 ± 1.2. Primary AF pattern
was paroxysmal (51.0%) and contraindications to long-term OAC were
recorded in 75.6% of patients. Baseline demographics and risk factors
are summarized in Table 1.
3.2. Asian vs. non-Asian subgroup analysis
Post-hoc subgroup analysis was performed according to implanting
geography as defined in the Statistical Analysis. One Australian patient
was identified as Asian ethnicity and was included in the appropriate
subgroup, yielding 107 Asian subjects and 94 non-Asian subjects.
Significant differences emerged between Asian and non-Asian sub-
jects, respectively, for underlying comorbidities with higher rates of
diabetes (46.7% vs. 19.1%, p b 0.0001), vascular disease (39.3% vs.
23.4%, p = 0.02), and labile INRs (20.6% vs. 4.3%, p = 0.0006), while
higher rates of prior TIA/ischaemic stroke were reported for non-
Asian subjects (30.8% vs. 45.7%, p = 0.04), concomitant drug use
(33.6% vs. 50.0%, p = 0.02) and alcohol abuse (2.8% vs. 13.8%, p = 0.01)
(Table 1).
3.3. Procedural success
A total of 201 patients underwent implant attempts, with a suc-
cessful implant achieved in 198 subjects (98.5%); 2 failures due to
unfavourable anatomy (non-Asian) and 1 due to mismatch between
device and LAA size (Asian). Closure (complete seal or leak b 5 mm)aide from ClinicalKey.com.au by Elsevier on October 29, 2020.
n. Copyright ©2020. Elsevier Inc. All rights reserved.
Table 1











Age ≥ 80 (%) 14.0 17.0 0.56
Gender (Male, %) 62.6 72.3 0.18
CHADS2 Score 2.5 ± 1.3 2.4 ± 1.4 0.49
CHA2DS2-VASc Score 4.1 ± 1.7 3.7 ± 1.6 0.08




HAS-BLED Score 2.2 ± 1.3 2.1 ± 0.9 0.66
HAS-BLED Score (%) 0.28
b3 (%) 65.4 73.4
≥3 (%) 34.6 26.6
CHF (%) 20.6 10.6 0.08
Hypertension (%) 84.1 83.0 0.85
Age ≥ 75(%) 38.3 34.0 0.56
Age 65–74 (%) 43.0 44.7 0.89
Diabetes (%) 46.7 19.1 b0.0001
History of TIA/stroke (%) 30.8 45.7 0.04
Vascular disease (%) 39.3 23.4 0.02
Abnormal renal function (%) 14.0 7.4 0.18
Abnormal liver function (%) 2.8 1.1 0.62
History of ischaemic/haemorrhagic stroke (%) 28.0 35.1 0.29
Prior major bleeding or predisposition to
bleeding (%)
19.6 18.1 0.86
Labile INRs (%) 20.6 4.3 0.0006
Concomitant use of drugs (%) 33.6 50.0 0.02
Alcohol abuse (%) 2.8 13.8 0.007
LV dysfunction (i.e. LVEF ≤ 40%) 7.5 5.4 0.58
AF pattern
% Paroxysmal AF 54.2 47.3 0.40
Values are mean ± SD or %. CHF = congestive heart failure; LVEF = left ventricular ejec-
tion fraction.
3K.P. Phillips et al. / IJC Heart & Vasculature 23 (2019) 100358was achieved in all successful cases, with no difference between sub-
groups (Table 2).
The majority of devices were successfully implanted without need
for recapture in Asian patients compared to non-Asian subjects (59.8%
vs. 43.0%, p = 0.06). Mean LAA diameter was significantly larger in
Asians (23.4± 4.1mmvs. 21.2± 3.2mm, p b 0.001) andmedian device
size used was 27mm for Asians and 24mm for non-Asians (p b 0.0001).
Therewere significant differences in oversizing of thedevice size tomax-
imum measured LAA diameter in Asian centres, but mean device com-
pression was similar for both groups(17 ± 7% vs. 17 ± 6%, p = 0.93).Table 2
Procedural results.







Complete seal or Jet size b 5 mm 100.0% (105/105) 100.0% (93/93) NS






Mean ± SD 23.4 ± 4.1 21.2 ± 3.2 b0.0001
Median 23.00 21.50
Last device size used (mm)
Mean ± SD 27.4 ± 3.4 25.3 ± 3.2 b0.0001⁎
Median 27 24
Compression of last device
size used (mm)
Mean ± SD 17 ± 7% 17 ± 6% 0.93
Median 16% 17%
p-Value = sample t-test across regions. LAA = left atrial appendage, mm= millimetres,
NS = not significant.
⁎ Wilcoxon Rank-Sum test used to compare medians.
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Baseline rates of anticoagulant or antiplatelet usage respectively for
Asian and non-Asians was as follows — warfarin 13.1% and 4.3%; Novel
oral anticoagulant (NOAC) 41.1% and 40.4%; dual-antiplatelet 15.0%
and 11.7%; single-antiplatelet 18.7% and 19.1%; no therapy 12.1% and
24.5%. Post-implant and follow-up medications regimens are shown
in Fig. 2 e-supplement. Anticoagulation with warfarin or NOAC was
discontinued in 95% of patients by 90 days post-implant (96% Asian
vs. 94% non-Asians) (Fig. 2B e-supplement). At last follow-up visit, the
rates of anticoagulant and antiplatelet therapy respectively for Asian
and non-Asians was as follows — warfarin 0% and 0%; NOAC 4.7% and
1.2%; dual-antiplatelet 55.8% and 3.5%; single-antiplatelet 36% and
77.6%; no therapy 3.5% and 17.6%.
3.5. Implant procedure safety
Procedure- or device-related SAEs within the first 7 and 30 days
occurred at a rate of 3.0% and 3.5%, respectively. Six patients experi-
enced SAEs on the day of the procedure: vascular damage to the groin
(n = 1, non-Asian), pericardial effusion requiring pericardiocentesis
(n=2, Asian), oesophageal tear due to TEE (n=1, Asian), hypotension
(n=1, non-Asian), and pulmonary oedema (n=1, non-Asian). All pa-
tients experienced full recovery except for the oesophageal tear (fatal
outcome on day 32). A femoral arteriovenous fistula was diagnosed
and treated on day 28 (n = 1, Asian). The procedure- or device-
related SAEs for Asian and non-Asian patients, respectively, at 7 and
30 days were 2.9% and 3.2% (p = 0.9) and 3.8% and 3.2% (p = 0.8).
3.6. Bleeding adverse events
Therewere 10major bleeding events over 2 years of follow-up, with
8 events in 6 non-Asians and 2 in Asianpatients (Table 3 e-supplement).
The overall major bleeding SAE rate at 30-dayswas 1.0% versus 3.2% and
at 12 months was 1.9% versus 5.4% for Asian and non-Asian patients,
respectively.
The expected rate of major bleeding for the cohort predicted by
HAS-BLED score [9] is 4.4 per 100-PY if takingwarfarin, however the ob-
served rate for the overall cohort was 2.2 per 100-PY [1.0 for Asian sub-
jects, 3.7 per 100-PY for non-Asian subjects (p=0.12)]. This represents
a 49% relative risk reduction for bleeding events but amore pronounced
relative risk reduction in Asian subjects as compared with non-Asians
(77% versus 14%) (Fig. 3).Fig. 3. Calculated major bleeding risk based on HAS-BLED score, actual observed major
bleeding rates and relative risk reduction for total cohort (left), Asian subgroup (centre)
and Non-Asian subgroup (right) after 2 years follow-up.
e from ClinicalKey.com.au by Elsevier on October 29, 2020.
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Of the 198 successful implants, 170 (86%) patients had subse-
quent follow-up imaging (90/106 Asians, 81/92 non-Asian) at a
mean follow-up time of 65.86 ± 30.18 days. Most imaging was per-
formed with TOE, but 10 patients at 1 centre were studied post-implant
with cardiac CT scans. No cases of device embolization were detected.
Successful closure of the LAAwith residual leak b 5mmwas documented
in 100% of patients with a follow-up TOE.
Device-associated thrombus was detected in 5 patients (2 Asian,
3 non-Asian) (2.5%) at follow-up at 7, 45, 97, 216 and 386 days post-
implant. Three patients were prescribed NOAC and 2 patients were
taking antiplatelet therapy at the time of the observed thrombus. No
neurological sequelae were detected and all thrombus were resolved
at subsequent TOE follow-up after continuation or adjustment of OAC.
3.8. Long-term follow-up
The mean follow-up time for the cohort was 684.1 ± 161.1 days
(median 731). Six ischaemic strokes occurred during follow-up, 1 TIA,
and no haemorrhagic stroke or intracranial bleeding events. Two strokes
occurred in Asian patients — right hemiparesis (day 6) in patient with
oesophageal tear from implant procedure, with eventual death (day
32) from sepsis andmulti-organ failure; and onepatientwith leftmiddle
cerebral artery territory infarction (day 212) while on dual-antiplatelet
therapy with eventual full neurological recovery. Four strokes occurred
in non-Asian patients, all with full recovery — an unclassified small
stroke (day 39) while on warfarin; a left frontal gyrus stroke (day 329)
while on aspirin, a left sided frontal stroke (day 350)while on no therapy
and a small middle cerebral artery territory stroke (day 414) while on
dual-antiplatelet therapy. A non-Asian patient experienced a TIA during
the procedure described as transient neurological deficit due to cerebral
air embolism. The expected rate of stroke/TIA/SE predicted [8] assuming
aspirin use is 8.5 per 100-PY, however the observed rate for the study
was 1.93 per 100-PY [1.0 per 100-PY for Asian subjects, 3.0 per 100-PY
for non-Asian subjects (p = 0.09)] (Table 4 e-supplement). This repre-
sents 77% relative risk reduction for the overall population, 89% reduc-
tion for Asian patients and 62% reduction for non-Asians (Fig. 4).Fig. 4. Calculated stroke/TIA/SE risk based on CHA2DS2-VASc score, actual observed stroke/TIA
Non-Asian subgroup (right) after 2 years follow-up. TIA = transient ischaemic attack, SE = sy
Downloaded for Anonymous User (n/a) at The University of Adel
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(p=0.06)]. Therewas one procedural-related death in an Asian subject
resulting from oesophageal tear as previously described. Other deaths
were reported as unrelated to the procedure or device: liver malig-
nancy, septic shock, thymus cancer, delirium, sudden cardiac arrest
(day 153), acute pulmonary oedema (day 729), old age, sepsis, septic
shock from pneumonia, head injury, and acute on chronic renal failure,
resulting in an all-cause death rate of 3.23 per 100-PYs.
4. Discussion
This prospectively collected registry provides new information on
the real-world use of LAA closure in an Asian population across multi-
ple regions. The novelty of the findings is especially important due to
increasing recognition of the challenges for stroke prevention in Asian
patients with NVAF, as evidence suggests a lower age threshold at
which increased risk is conferred for Asians (from age 50 years) com-
pared with non-Asians [1,3]. This creates challenges from the potential
increased duration of exposure to anticoagulation and long-term com-
pliance. Rates of under-treatment with anticoagulation remain stub-
bornly high in Asian countries despite the global penetration of
NOACs into clinical practice [10]. Compared to non-Asians, Asians are
at significantly higher risk of warfarin-related intracranial bleeding
(HR = 4.06) [2]. Although NOAC trial meta-analysis demonstrated
greater proportional reduction compared with warfarin for rates of
intracranial haemorrhage for Asian patients versus non-Asians, the ab-
solute rates still remain higher [4,11]. Attention has also been focused
on the possible link between macro and micro-angiopathies which
are more prevalent in Asian populations and show an increased risk
of intracranial haemorrhage [11]. Results from a Korean study sug-
gested that among NVAF patients with a recent ischaemic stroke,
17.2% were classified as AF-unrelated, highlighting the complexity
surrounding mixed aetiologies of stroke in Asians [12]. These data
also highlight the significant numbers of Asian patients who may
have contraindications to long-term anticoagulation; conversely LAA
closure can achieve annual rates of ischaemic stroke and bleeding
around 1% without an increased iatrogenic risk of intracranial bleeding
and secured compliance [5]. The results in the current study are/SE rate and the relative risk reduction for total cohort (left), Asian subgroup (centre) and
stemic embolism, RR = relative risk.
aide from ClinicalKey.com.au by Elsevier on October 29, 2020.
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annual stroke rate of 2.13% for a cohort of secondary prevention pa-
tients (mean CHA2DS2-VASc score of 4.09 ± 1.06) who underwent
WATCHMAN LAA closure [13]. Mortality rates in Asian patients trended
higher than non-Asian subjects in the current study although did not
achieve statistical significance (p = 0.06) with most deaths non-
cardiac related. A high 1-year mortality rate of 9.8% was noted in
the EWOLUTION registry [6] with the probable explanation being
OAC-contraindicated patients generally having higher comorbidity
profiles and lower life expectancy.
4.1. Bleeding rates
The rate of major bleeding events in the study was 2.2 per 100-PY.
There are several potential reasons for the small but significant ongoing
bleeding rates in the study. Firstly, a proportion of events can be attrib-
uted to adverse effects of the post-implant medication regimen, likely
impacting the short-term bleeding events. One study has examined
the potential for using simplified or shortened oral anticoagulation
or antiplatelet regimens in the post-implant period of LAA closure
and healing [14]. Increased risk of intracranial haemorrhage has
been noted for warfarin [2], NOACs [9] and aspirin [15] in Asian popu-
lations undergoing secondary stroke prevention, however no increased
risk has been shown for clopidogrel [16]. This requires further consid-
eration for post-implant strategies in Asian patients that may limit
bleeding risk in this specific population. Secondly, the cohort includes
significant numbers of patients with a documented history of major
bleeding event. Unsurprisingly, over half of the bleeding events were
attributable to a gastrointestinal cause, and most of these cases a
history of gastrointestinal bleeding was the main indication for LAA
closure. As rates of gastrointestinal bleeding are reported to be higher
in non-Asian patients taking NOACs [4], the strategy of mechanical clo-
sure can provide an important stroke prevention alternative for these
patients.
4.2. Procedural safety in Asian patients
Although the 7-day peri-procedural complication rate was low at
3.0%, there was a procedure-related death due to complications from
a tear related to TOE performed to guide the implant. TOE technique
during LAA device implant differs from typical diagnostic study
due to the requirement for the patient to be supine, heparinised and
may involve a more prolonged period of oesophageal manipulation.
Oesophageal injury related to TOE was reported in one other small
study on LAA device closure with the Amplatzer cardiac plug (Abbott,
Abbott Park, IL) performed in 20 Asian patients [17]. Comparatively,
rates of oesophageal injury in other WATCHMAN studies with predom-
inantly non-Asian populations have been extremely low (1/542 in
PROTECT AF, 0/1021 EWOLUTION) [5,6]. Some centres have suggested
the use of micro-TOE probes to reduce oesophageal injury rates; fur-
ther study of alternative imaging modality in this population deserves
consideration.
4.3. LAA dimension in Asian patients
Another notable finding was a larger mean LAA ostial diameter and
larger median device size used in Asian patients compared to non-
Asians. This is important as LAA sizewas first recognized as an indepen-
dent risk factor for stroke in the SPAF study [18]. Maximal LAA ostial
diameter has previously been shown to correlate with left atrial volume
and to be larger for patients with persistent as compared with paroxys-
mal forms of AF [19]. Furthermore, left atrial volume has also been
shown to correlate with body mass index (BMI) [20]. However, no
significant difference was apparent between the proportion of Asian
vs. non-Asian patients with persistent forms of AF. Although BMI was
not collected, Asian populations are generally smaller stature andDownloaded for Anonymous User (n/a) at The University of Adelaid
For personal use only. No other uses without permission. Clower BMI than comparable Western cohorts, so neither factor would
appear to be an explanation for differences. The findinghas practical im-
plications for LAA device occlusion in Asian patients but warrants
further research into ethnic differences in left atrial remodelling and
stroke risk.
4.4. Clinical implications
While the effectiveness of OAC as a stroke reduction strategy in
NVAF patients has been well established, the inherent bleeding risks
still provide a conundrum for those at higher risk of bleeding complica-
tions, leading to variable physician and patient compliance especially
in Asian regions [10]. LAA closure can provide effective stroke risk re-
duction without the bleeding risks associated with long-term pharma-
cological therapy, but until now has limited outcome data in Asian
populations. This prospective real-world registry demonstrates that
Asian patients appear to derive the same stroke benefit from LAA clo-
sure as non-Asians, while achieving the expected bleeding benefits
associated with limited exposure to anticoagulation. Current Clinical
Guidelines support the use of left atrial appendage device closure for
patients with high stroke risk and contraindications to long-term oral
anticoagulant treatment [21]. The current study provides additional
evidence that the Guidelines are also directly applicable to patients of
Asian ethnicity.
4.5. Study limitations
There are inherent limitations that arise from a real-world registry
design including non-conformity of treatment (e.g. variation in post-
discharge OAC) and non-conformity of follow-up (e.g. incomplete TOE
follow-up). Additionally, all TOE measurements are subject to operator
interpretation and imaging system variability since no independent
image adjudication was employed. Country of origin was used as a sur-
rogate for Asian ethnicity, which is generally considered valid due to
low rates of ethnic diversity in Asian countries, however future studies
should specifically define race. While this is the largest LAA closure
registry in the region, the cohort size and infrequent event rates limits
subgroup analyses. The predictive accuracy of estimating expected
stroke and bleeding risks bymean CHA2DS2-VASc and HAS-BLED scores
is unknown in Asian patients in the setting of NOAC rather than warfa-
rin use. Thus the potential for under or over-estimation of risk reduction
with LAAC cannot be excluded.
Because of the recognized differences in stroke epidemiology and re-
sponses to treatment across different racial groups, further large-scale
studies are required. As new therapies for atrial fibrillation penetrate
Asian countries, there will be better scope to study potential regional
differences across Asia.
5. Conclusions
Real world experience of LAA closure withWATCHMAN has demon-
strated a high successful implant rate and low peri-procedural risk
in a predominantly Asian cohort. Consistent with other WATCHMAN
studies, long-term outcomes show efficacious stroke prevention with
low bleeding risks for patients with Asian ethnicity.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijcha.2019.100358.
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